Home › Compare › ROXIF vs JNJ

ROXIF vs JNJ: Dividend Comparison 2026

ROXIF yields 285714.29% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ROXIF wins by $1.734986541242196e+31M in total portfolio value
10 years
ROXIF
ROXIF
● Live price
285714.29%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.734986541242196e+31M
Annual income
$17,337,928,197,276,910,000,000,000,000,000,000,000.00
Full ROXIF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ROXIF vs JNJ

📍 ROXIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodROXIFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ROXIF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ROXIF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ROXIF
Annual income on $10K today (after 15% tax)
$24,285,714.29/yr
After 10yr DRIP, annual income (after tax)
$14,737,238,967,685,373,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, ROXIF beats the other by $14,737,238,967,685,373,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ROXIF + JNJ for your $10,000?

ROXIF: 50%JNJ: 50%
100% JNJ50/50100% ROXIF
Portfolio after 10yr
$8.67493270621098e+30M
Annual income
$8,668,964,098,638,455,000,000,000,000,000,000,000.00/yr
Blended yield
99.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ROXIF
No analyst data
Altman Z
2.5
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ROXIF buys
0
JNJ buys
0
No recent congressional trades found for ROXIF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricROXIFJNJ
Forward yield285714.29% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$1.734986541242196e+31M$20.0K ✓
Annual income after 10y$17,337,928,197,276,910,000,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$1.734908400352195e+31M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ROXIF vs JNJ ($10,000, DRIP)

YearROXIF PortfolioROXIF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$28,582,129$28,571,428.57$10,676$355.77+$28.57M → ROXIF
2$76,351,353,429$76,320,770,551.21$11,407$389.39+$76351.34M → ROXIF
3$190,619,493,207,524$190,537,797,259,355.30$12,198$426.53+$190619493.20M → ROXIF
4$444,781,927,427,195,200$444,577,964,569,463,100.00$13,056$467.62+$444781927427.18M → ROXIF
5$969,967,353,346,567,200,000$969,491,436,684,220,000,000.00$13,987$513.12+$969967353346567.13M → ROXIF
6$1,976,961,629,315,093,000,000,000$1,975,923,764,247,012,300,000,000.00$14,998$563.56+$1976961629315092992.00M → ROXIF
7$3,765,923,944,594,039,000,000,000,000$3,763,808,595,650,671,000,000,000,000.00$16,098$619.52+$3.765923944594039e+21M → ROXIF
8$6,704,681,437,057,684,000,000,000,000,000$6,700,651,898,436,968,000,000,000,000,000.00$17,295$681.69+$6.704681437057683e+24M → ROXIF
9$11,156,275,836,497,016,000,000,000,000,000,000$11,149,101,827,359,364,000,000,000,000,000,000.00$18,599$750.82+$1.1156275836497015e+28M → ROXIF
10$17,349,865,412,421,960,000,000,000,000,000,000,000$17,337,928,197,276,910,000,000,000,000,000,000,000.00$20,022$827.78+$1.734986541242196e+31M → ROXIF

ROXIF vs JNJ: Complete Analysis 2026

ROXIF — Stock

Caspian Sunrise plc engages in the exploration and production of crude oil in Central Asia. The company has a 99% interest in its principal asset, the BNG Contract Area, which covers an area of 1,561 square kilometers located in the Mangistau Oblast in the west of Kazakhstan. The company was formerly known as Roxi Petroleum Plc and changed its name to Caspian Sunrise plc in March 2017. Caspian Sunrise plc was incorporated in 2006 and is based in London, the United Kingdom.

Full ROXIF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ROXIF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ROXIF vs SCHDROXIF vs JEPIROXIF vs OROXIF vs KOROXIF vs MAINROXIF vs ABBVROXIF vs MRKROXIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.